First European market launch of Alvesco

Altana Pharma launches Alvesco in the United Kingdom, Launch in Germany imminent

19-Jan-2005

Altana AG has announced that Alvesco® (Ciclesonide), a novel inhaled corticosteroid (ICS) for the treatment of adults (18+ years) suffering from persistent asthma is now available for the first time in the United Kingdom (UK). Altana Pharma also received the national marketing license for Germany and will start to market Alvesco® in Germany in February. Further launches will follow during the year in Europe and across the world.

More than 300 million people worldwide suffer from asthma, thereof approx. 10 million patients in the UK. IMS data indicate that the UK is the largest market in Europe for asthma medication. The market in mono-therapy inhaled corticosteroids (ICS Mono) represented a value of some EUR1 billion in 2003, of which the UK accounted for about 30 percent.

Other news from the department research and development

Most read news

More news from our other portals

So close that even
molecules turn red...